Login to Your Account

Kalvista lures Merck to potential $752M DME collaboration, option deal

By Marie Powers
News Editor

Tuesday, October 10, 2017

Shares of Kalvista Pharmaceuticals Inc. soared to $15.80 – and closed at $10.19 for a gain of $2.81 after Merck & Co. Inc. agreed to pay a $37 million nonrefundable up-front fee and up to $715 million in milestone payments as part of a collaboration to advance KVD-001, an intravitreal injection candidate to treat DME.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription